- Home
- Industry Reports
- Diagnostics
- Healthcare
- Companion Diagnostics Market – share, Outlook, Trends, Size and Forecast (2024 – 2032)
The Global Companion Diagnostics Market might grow up to USD6.53 billion at a CAGR of 26.3% from 2018-2024. Companion Diagnostics are an essential aspect of the personalised treatment approach and are crucial for forecasting the therapeutic response to a particular drug. Companion Diagnostics are in-Vitro diagnostics that produce knowledge about therapeutic responses of patients for a specific treatment. Companion Diagnostics is used to identify suitable patients to whom particular drugs can be managed, and it monitors the prognosis of the effects of the drugs on a disease.
Global Companion Diagnostics Market Share:
Companion Diagnostics Market mainly focuses on top manufacturers in the global market, with production, price and revenue of market share for each manufacturer.
Global Companion Diagnostics Market Size:
North America has the highest market share among all the regions. Geographically, South America and Middle East Asia countries are fastest growing regions. Globally, Companion Diagnostics have several advantages like there is a rapid increase of offers and profit-oriented of the drug prospects will generate drugs with a better therapeutic efficiency in a faster and cost-effective way.
Global Companion Diagnostics Market Growth:
The Oncology is primarily attributed to the growing incidence of cancer that enhanced the focus on cancer research and also widens the role of companion diagnostics in the field. Based on the end-user, the pharmaceutical and biopharmaceutical companies segment reckons for the most significant share of the market. Developments in predictive biomarkers play a vital role in the successful profit-oriented of companion diagnostics. There are two dominant therapy areas: Oncology and neurology. There is an increase in growth strategies among vendors.
Global Companion Diagnostics Market Industry Analysis:
Indication, Technology, and Geography segment the Global Companion Diagnostics Market size. For detecting various cancer, biomarkers have been developed by Companion Diagnostics. Oncology is the highest revenue generating segment. Majority of the companies are focusing on collaborations with drug companies to develop companion diagnostics for their pipeline drugs.
Global Companion Diagnostics Market Outlook:
Global Companion Diagnostics Market Industry Analysis mainly focuses on market trends, leading players, supply chain trends, Key Developments, and technological innovations. The Market Sizing analysis includes both top-down and bottom-up approaches to data validation and accuracy measures.
Global Companion Diagnostics Market Trends:
Abbott develops local partnerships for long-term improvements to public healthcare, Agilent Technologies, Inc. receives multiple innovation awards from the analytical scientist.
Global Companion Diagnostics Market Research report includes:
- An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
- To have complete market analysis through industry value chain analysis, Porter’s five, PESTLE, SWOTanalysis, and Y-o-Y analysis.
- Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year–On–Year
- Identifying DROC in the current market and their impact in altering the market dynamics.
- Competitive landscape analysis to identify the merger and acquisition which will have a comparative financial study with significant competitors.
- Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
- Identify the latest developments, market shares and strategies that are employed by the major market players, such as
- Abbott Laboratories
- Advanced Cell Diagnostics Inc.
- Agilent Technologies, Inc.
- Biomérieux
Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter’s Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 Pestle Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threat
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
Chapter 5 Market Segmentation Analysis
Chapter 6 Market Segmentation, By Type
6.1 Introduction
6.2 Iodinated Contrast
6.3 Gadolinium-Based Contrast Media
6.4 Microbubble Contrast Media
6.5 Barium-Based Contrast Media
6.6 Y-o-Y Growth Analysis
6.7 Market Attractiveness Analysis
Chapter 7 Global Companion Diagnostics Market, By Strategic Analysis
7.1 Introduction
7.2 Value Chain Analysis
7.3 Pricing Analysis
7.4 Opportunities Analysis
7.5 Others
Chapter 8 Global Companion Diagnostics Market, By Technology
8.1 Introduction
8.2 Polymerase Chain Reaction (PCR)
8.3 Sequencing-based
8.4 In Situ Hybridization
8.5 Immunohistochemistry
Chapter 9 Global Companion Diagnostics Market, By End-Users
9.1 Introduction
9.2 Pharmaceutical Companies
9.3 Reference Laboratories
9.4 cathode-ray oscilloscope(CRO)
9.5 Hospitals
Chapter 10 Global Companion Diagnostics Market, By Indication
10.1 Introduction
10.2 Breast Cancer
10.3 Lung Cancer
10.4 Melanoma
10.5 Gastric Cancer
10.6 Colorectal Cancer
Chapter 11 Market Segmentation, By Geography
11.1 North America
11.1.1 Introduction
11.1.2 United States
11.1.3 Canada
11.1.4 Mexico
11.1.5 Others
11.2 Europe
11.2.1 Introduction
11.2.2 U.K
11.2.3 Spain
11.2.4 Italy
11.2.5 France
11.2.6 Russia
11.2.7 Others
11.3 Asia-Pacific
11.3.1 Introduction
11.3.2 China
11.3.3 India
11.3.4 Japan
11.3.5 Australia
11.3.6 Others
11.4 South America
11.4.1 Introduction
11.4.2 Brazil
11.4.3 Argentina
11.4.4 Others
11.5 The Middle East & Africa
11.5.1 Introduction
11.5.2 Middle-East
11.5.3 Africa
11.5.4 Others
Chapter 12 Competitive Landscape
12.1 Mergers & Acquisitions, Joint Ventures, Collaborations, and Agreements
12.2 Market Share Analysis
12.3 Strategies Adopted By Top Companies
Chapter 13 Company Profiles
13.1. Abbott Laboratories
13.1.1. Company Overview
13.1.2. Financial Performance
13.1.3. Product Benchmarking
13.1.4. Strategic Initiative
13.2. Advanced Cell Diagnostics Inc.
13.3. Agilent Technologies, Inc.
13.4. Biomérieux
13.5. Biogenex Laboratories
13.6. Danaher Corporation
13.7. Roche Diagnostics
13.8. Thermo Fisher Scientific, Inc.
13.9. GE Healthcare
13.10. R-Biopharm AG
13.11 Myriad Genetics, Inc.
13.12. Qiagen N.V.
13.13. Cypher Genomics
13.14. Flagship Biosciences
13.15. Applied Proteomics
13.16. Ignyta, Inc.
13.17. Madison Vaccines, Inc.
13.18. Ventana Medical Systems, Inc.
13.19 A&G Pharmaceutical, Inc.
13.20 EKF Diagnostics Holdings plc.
Chapter 14 Market Estimates and Forecast
14.1 Market Estimates and Forecast 2018-2024 (USD Million)
14.1.1 Market Estimation and Forecast by Strategic Analysis 2018-2024 (USD Million)
14.1.2 Market Estimates and Forecast by Technology 2018-2024 (USD Million)
14.1.3 Market Estimates and Forecast by Indication 2018-2024 (USD Million)
14.1.4 Market Estimates and Forecast by End-Users 2018-2024 (USD Million)
14.1.5 Market Estimates and Forecast by Geography 2018-2024 (USD Million)
14.1.6 Market Estimates and Forecast by Company 2018-2024 (USD Million)
Chapter 15 Market Insights
15.1 Insights of Industry Experts
15.2 Analyst Opinion (Market Understanding)
15.3 Investment Opportunities
Chapter 16 Appendix
16.1 List of Tables
16.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Global Report
$2,700.00 – $8,100.00
- EUR: €2,534.50 - €7,603.49
- INR: ₹225,374.60 - ₹676,123.80
- AED: د.إ9,909.00 - د.إ29,727.00
- GBP: £2,170.04 - £6,510.11
Additional information
Report Type | Extensive Report, Miniature report, Snapshot Report |
---|---|
Licence | Single User License, Team License, Corporate License |
The Global Companion Diagnostics Market might grow up to USD6.53 billion at a CAGR of 26.3% from 2018-2024. Companion Diagnostics are an essential aspect of the personalised treatment approach and are crucial for forecasting the therapeutic response to a particular drug. Companion Diagnostics are in-Vitro diagnostics that produce knowledge about therapeutic responses of patients for a specific treatment. Companion Diagnostics is used to identify suitable patients to whom particular drugs can be managed, and it monitors the prognosis of the effects of the drugs on a disease.
Global Companion Diagnostics Market Share:
Companion Diagnostics Market mainly focuses on top manufacturers in the global market, with production, price and revenue of market share for each manufacturer.
Global Companion Diagnostics Market Size:
North America has the highest market share among all the regions. Geographically, South America and Middle East Asia countries are fastest growing regions. Globally, Companion Diagnostics have several advantages like there is a rapid increase of offers and profit-oriented of the drug prospects will generate drugs with a better therapeutic efficiency in a faster and cost-effective way.
Global Companion Diagnostics Market Growth:
The Oncology is primarily attributed to the growing incidence of cancer that enhanced the focus on cancer research and also widens the role of companion diagnostics in the field. Based on the end-user, the pharmaceutical and biopharmaceutical companies segment reckons for the most significant share of the market. Developments in predictive biomarkers play a vital role in the successful profit-oriented of companion diagnostics. There are two dominant therapy areas: Oncology and neurology. There is an increase in growth strategies among vendors.
Global Companion Diagnostics Market Industry Analysis:
Indication, Technology, and Geography segment the Global Companion Diagnostics Market size. For detecting various cancer, biomarkers have been developed by Companion Diagnostics. Oncology is the highest revenue generating segment. Majority of the companies are focusing on collaborations with drug companies to develop companion diagnostics for their pipeline drugs.
Global Companion Diagnostics Market Outlook:
Global Companion Diagnostics Market Industry Analysis mainly focuses on market trends, leading players, supply chain trends, Key Developments, and technological innovations. The Market Sizing analysis includes both top-down and bottom-up approaches to data validation and accuracy measures.
Global Companion Diagnostics Market Trends:
Abbott develops local partnerships for long-term improvements to public healthcare, Agilent Technologies, Inc. receives multiple innovation awards from the analytical scientist.
Global Companion Diagnostics Market Research report includes:
- An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
- To have complete market analysis through industry value chain analysis, Porter’s five, PESTLE, SWOTanalysis, and Y-o-Y analysis.
- Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year–On–Year
- Identifying DROC in the current market and their impact in altering the market dynamics.
- Competitive landscape analysis to identify the merger and acquisition which will have a comparative financial study with significant competitors.
- Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
- Identify the latest developments, market shares and strategies that are employed by the major market players, such as
- Abbott Laboratories
- Advanced Cell Diagnostics Inc.
- Agilent Technologies, Inc.
- Biomérieux
Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter’s Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 Pestle Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threat
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
Chapter 5 Market Segmentation Analysis
Chapter 6 Market Segmentation, By Type
6.1 Introduction
6.2 Iodinated Contrast
6.3 Gadolinium-Based Contrast Media
6.4 Microbubble Contrast Media
6.5 Barium-Based Contrast Media
6.6 Y-o-Y Growth Analysis
6.7 Market Attractiveness Analysis
Chapter 7 Global Companion Diagnostics Market, By Strategic Analysis
7.1 Introduction
7.2 Value Chain Analysis
7.3 Pricing Analysis
7.4 Opportunities Analysis
7.5 Others
Chapter 8 Global Companion Diagnostics Market, By Technology
8.1 Introduction
8.2 Polymerase Chain Reaction (PCR)
8.3 Sequencing-based
8.4 In Situ Hybridization
8.5 Immunohistochemistry
Chapter 9 Global Companion Diagnostics Market, By End-Users
9.1 Introduction
9.2 Pharmaceutical Companies
9.3 Reference Laboratories
9.4 cathode-ray oscilloscope(CRO)
9.5 Hospitals
Chapter 10 Global Companion Diagnostics Market, By Indication
10.1 Introduction
10.2 Breast Cancer
10.3 Lung Cancer
10.4 Melanoma
10.5 Gastric Cancer
10.6 Colorectal Cancer
Chapter 11 Market Segmentation, By Geography
11.1 North America
11.1.1 Introduction
11.1.2 United States
11.1.3 Canada
11.1.4 Mexico
11.1.5 Others
11.2 Europe
11.2.1 Introduction
11.2.2 U.K
11.2.3 Spain
11.2.4 Italy
11.2.5 France
11.2.6 Russia
11.2.7 Others
11.3 Asia-Pacific
11.3.1 Introduction
11.3.2 China
11.3.3 India
11.3.4 Japan
11.3.5 Australia
11.3.6 Others
11.4 South America
11.4.1 Introduction
11.4.2 Brazil
11.4.3 Argentina
11.4.4 Others
11.5 The Middle East & Africa
11.5.1 Introduction
11.5.2 Middle-East
11.5.3 Africa
11.5.4 Others
Chapter 12 Competitive Landscape
12.1 Mergers & Acquisitions, Joint Ventures, Collaborations, and Agreements
12.2 Market Share Analysis
12.3 Strategies Adopted By Top Companies
Chapter 13 Company Profiles
13.1. Abbott Laboratories
13.1.1. Company Overview
13.1.2. Financial Performance
13.1.3. Product Benchmarking
13.1.4. Strategic Initiative
13.2. Advanced Cell Diagnostics Inc.
13.3. Agilent Technologies, Inc.
13.4. Biomérieux
13.5. Biogenex Laboratories
13.6. Danaher Corporation
13.7. Roche Diagnostics
13.8. Thermo Fisher Scientific, Inc.
13.9. GE Healthcare
13.10. R-Biopharm AG
13.11 Myriad Genetics, Inc.
13.12. Qiagen N.V.
13.13. Cypher Genomics
13.14. Flagship Biosciences
13.15. Applied Proteomics
13.16. Ignyta, Inc.
13.17. Madison Vaccines, Inc.
13.18. Ventana Medical Systems, Inc.
13.19 A&G Pharmaceutical, Inc.
13.20 EKF Diagnostics Holdings plc.
Chapter 14 Market Estimates and Forecast
14.1 Market Estimates and Forecast 2018-2024 (USD Million)
14.1.1 Market Estimation and Forecast by Strategic Analysis 2018-2024 (USD Million)
14.1.2 Market Estimates and Forecast by Technology 2018-2024 (USD Million)
14.1.3 Market Estimates and Forecast by Indication 2018-2024 (USD Million)
14.1.4 Market Estimates and Forecast by End-Users 2018-2024 (USD Million)
14.1.5 Market Estimates and Forecast by Geography 2018-2024 (USD Million)
14.1.6 Market Estimates and Forecast by Company 2018-2024 (USD Million)
Chapter 15 Market Insights
15.1 Insights of Industry Experts
15.2 Analyst Opinion (Market Understanding)
15.3 Investment Opportunities
Chapter 16 Appendix
16.1 List of Tables
16.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Our Clientele
Exclusive Benefits
Credibility and Transparency
We actively recruit consumers, business professionals, and hard-to-reach individuals as members of our research panels, and we build trusted, ongoing relationships with them. Thus we provide the complete list of primary and secondary data sources in the report to maintain the transparency and to assure the credibility.
Exhaustive Coverage
Detailed and extensive coverage in the geography.Survey consultation for brand tracking, concept testing, consumer behaviour, and more, we have you covered with market research services that scale to meet your needs.
Competitive Edge
Our reports cover most recent updates in the market till the date of the purchase. We identify, gather and timely deliver analysis on impact of unprecedented decisions of CXOs in COVID-19 catastrophe on many businesses, their clients and their clients' clients without additional cost.
Golden Opportunities
A comprehensive strategic sieve analysis of the market by our analysts and consultants, aided by AI tools helps us find the non-obvious, golden and emerging opportunities for you to evaluate.
Top-notch Reports Guaranteed
70% of our research is exclusive; no other research firm has the depth and breadth of our research.
Post Purchase Support
Post-purchase support is provided for all our reports, for three months from the date of purchase, where related queries will be answered within 24 business hours over telephone or email.